[Renal cell carcinoma 2008. Histopathology, molecular genetics and new therapeutic options].
By integrating genetic data into the traditional histology and immunohistochemistry-based classification system the revised WHO-classification of malignant tumours (2004) defined additional renal cell carcinoma subtypes, thereby enabling the application of additional diagnostic procedures. Therapy for advanced clear cell renal cell carcinoma has also seen significant progress. This report focuses on these developments, pinpoints current obstacles and provides future prospects.
Hammerschmied
C G
CG
Pathologisches Institut, Universitätsklinikum Erlangen, Krankenhausstrasse 12, 91054, Erlangen.
Walter
B
B
Hartmann
A
A
D000236:Adenoma / Q000235:genetics / Q000473:pathology; D018249:Adenoma, Oxyphilic / Q000235:genetics / Q000473:pathology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000145:classification / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D002869:Chromosome Aberrations; D002893:Chromosomes, Human, Pair 3; D002895:Chromosomes, Human, Pair 5; D002896:Chromosomes, Human, Pair 6; D041321:Chromosomes, Human, X; D003937:Diagnosis, Differential; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000145:classification / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D014178:Translocation, Genetic
D000970:Antineoplastic Agents